Search
From Indianapolis: Serial entrepreneur Derek Small publicly launched a new neuroscience company with $90M earlier this summer, Syndeio Biosciences. He tells us about it and talks Indiana biotech.
He discusses the idea behind Syndeio, which focuses on synaptic function and has a lead program in major depressive disorder. Plus, other...
Aug 5
From Indianapolis: Adipo Therapeutics is approaching the obesity space by trying to turn energy storing 'white' fat into energy burning 'brown' fat
CEO Karen Wurster describes the science behind the company, which recently presented proof-of-concept data from human cells at the ADA...
Aug 5
The Indiana Biosciences Research Institute is a central hub for the biotech scene in Indiana - its CEO describes what it is all about, and the status of biotech here today
IBRI CEO Alan Palkowitz describes the work that takes place at the IBRI, which includes both the institute's own research and how it acts...
Aug 5
BiotechTV visits Indiana University School of Medicine's Stark Neurosciences Research Institute and discusses the latest in Alzheimer's research with its executive director, Bruce Lamb
Dr. Lamb, a noted expert in neuroscience and Alzheimer's research, introduces us to Stark and describes the investment in people and...
Aug 4
Former NIH Director and Co-Founder of ModeX Therapeutics Elias Zerhouni shares his take on possible NIH cuts and the state of science in the United States, and working on multispecifics at his company
He highlights his new memoir, Disease Knows No Politics, and gives his opinion on what is at stake in preserving NIH and other scientific...
Jul 30
As independent tenant advocates, Savills can help biotech and pharma companies make their real estate footprint align with their objectives and be more efficient
Austin Barrett, Vice Chairman and Head of Life Sciences, describes the type of work Savills does for clients today, including...
Jul 30
BioVenture VoiCes Episode 23: a16z's Vineeta Agarwala
Still a practicing physician today, Vineeta Agarwala describes her educational background and early career, including experiences at the...
Jul 28
AI x Bio Summit: Proscia CEO David West describes how AI in pathology is not just helping pathologists find disease, but can also help get the right drug to the right patient
He describes how computing power in pathology is augmenting the work that pathologists traditionally do, but also is becoming an...
Jul 24
Monte Rosa Therapeutics' CEO Markus Warmuth updates us on the company's progress in developing molecular glue degraders
The company, which recently had a paper earn a spot on the cover of Science, is progressing ahead with both I&I and oncology indications....
Jul 24
Abivax CEO Marc de Garidel discusses Obefazimod's phase 3 trial result in ulcerative colitis, and what is next for the company
He covers the mechanism of action, this week's efficacy and safety data, what it might mean for the maintenance trial that will read out...
Jul 24
AI x Bio Summit: Recursion's Chief R&D Officer & CCO Najat Khan describes how the company leverages AI - including in both the dry lab and the wet lab, and all through clinical trials
She describes Recursion's work, and what the acquisition of Exscientia has brought to the company. Plus, how AI can not only help with...
Jul 23
After receiving a CRL for its RP1 oncolytic immunotherapy yesterday, the CEO of Replimune walks us through the program's timeline and history, and what this might mean for its future
CEO Sushil Patel walks us through the decisions behind the design of the IGNYTE phase 1/2 study and the ongoing IGNYTE-3 study, he gives...
Jul 23
AI x Bio Summit: The CEO of Alto Neuroscience, which is working on precision medicine for neuroscience, talks about how the company is using AI and machine learning in its development programs
Amit Etkin says Alto Neuro is trying to use machine learning to understand signals from the complexity of the brain, and the company is...
Jul 22
NYSE Strategist Eric Criscuolo shares his take on the markets and biotech sentiment
He discusses the importance of interest rates to high risk sectors like biotech, and comment on how our sector has not performed lately...
Jul 22
AI x Bio Summit: The Co-Founder and Head of Machine Learning at Dyno Therapeutics describes how his company is using AI to design better capsids
Sam Sinai talks about how capsids are being more precisely designed today, which is allowing drug developers to better target them to...
Jul 22
RBC's Healthcare Desk Strategist Chris McCarthy discusses biotech sentiment, and positioning around key events and catalysts that are upcoming
He highlights recent M&A, but also notes how the sector has not been reliant on deals like it has in the past. Plus, discussing how...
Jul 22
AI x Bio Summit: Nimbus Therapeutics' new CEO and President of R&D describe how AI is, an isn't, used in the company's R&D process
CEO Abbas Kazimi and President of R&D Peter Tummino discuss how AI integrates into their discovery and clinical development work, and...
Jul 22
Metsera CEO Whit Bernard shares an update on the company's obesity programs, and comments on the state of the field post ADA
He describes data that Mestera presented at ADA for its monthly-dosed GLP1 and also its amylin analog. Plus, recent learnings about the...
Jul 22
Cambridge, MA based Avalyn Pharma is developing a novel inhaled formulation of pirfenidone and other medicines for pulmonary fibrosis - it just raised a $100M (up round) series D financing
CEO Lyn Baranowski describes the therapy and demonstrates the nebulizer that delivers it, and explains how Avalyn's method is designed increase the dose patients can take vs oral therapies and, therefore, increase the therapeutic value.
Jul 22
Jon Norris shares highlights from his 2025 Mid-Year Venture Healthcare Report
He discusses trends in deal size, therapeutic focus, IPOs, and more. DOWNLOAD THE FULL REPORT #sponsored
Jul 21
.png){kind=logo}
